Regarding the pharmacological properties of antipsychotics, all of the following statements are TRUE EXCEPT:

Explanation

## Pharmacology of Antipsychotics: Receptor Selectivity and Clinical Implications ### Understanding D2 Receptor Selectivity **Key Point:** First-generation (typical) antipsychotics are NON-SELECTIVE dopamine antagonists — they block D2 receptors equally across all brain regions, including the nigrostriatal pathway. This is why they cause extrapyramidal side effects (EPS). The statement that first-generation antipsychotics have "higher affinity for D2 receptors in the mesolimbic pathway compared to the nigrostriatal pathway" is **FALSE**. This is a common misconception. The therapeutic selectivity of antipsychotics is NOT due to regional D2 selectivity but rather: 1. **Mesolimbic dopamine hyperactivity** is the presumed pathophysiology of positive symptoms 2. **Nigrostriatal dopamine** is needed for motor control 3. First-generation drugs block both equally → EPS is inevitable 4. Second-generation drugs achieve better therapeutic-to-EPS ratio through **rapid dissociation kinetics** and **5-HT2A antagonism** (which may facilitate dopamine release in motor circuits) ### Why the Other Options Are Correct | Feature | First-Generation | Second-Generation | Clozapine | |---------|------------------|-------------------|----------| | D2 selectivity by region | None (blocks all regions equally) | None (but rapid off-rate helps) | Lowest D2 affinity of all | | 5-HT2A antagonism | Minimal/absent | Present (key mechanism) | Present | | EPS risk | High | Low | Lowest (0.3% tardive dyskinesia) | | Treatment-resistant efficacy | Poor | Moderate | Gold standard (30–50% response) | **High-Yield:** The "atypicality" of second-generation antipsychotics comes from **kinetic selectivity** (fast dissociation from D2) and **serotonin antagonism**, NOT regional dopamine selectivity. **Clinical Pearl:** Clozapine is the only antipsychotic with proven efficacy in treatment-resistant schizophrenia (defined as failure of ≥2 adequate trials of different antipsychotics). Its low D2 affinity and unique pharmacology (muscarinic, alpha-adrenergic, and 5-HT antagonism) make it uniquely effective but also carry metabolic and hematologic risks. ### Why Statement 3 (Clozapine) Is Correct Clozapine has the lowest incidence of tardive dyskinesia (~0.3% per year) and may even reverse existing tardive dyskinesia. It is the gold standard for treatment-resistant schizophrenia. ### Why Statement 2 (Second-Generation Mechanism) Is Correct The lower EPS risk of second-generation antipsychotics is explained by: - Rapid dissociation from D2 (allowing brief dopamine signaling in motor circuits) - 5-HT2A antagonism (may enhance dopamine release in nigrostriatal pathway) - Lower D2 occupancy required for antipsychotic effect ### Why Statement 4 (Equipotent Doses) Is Correct When first-generation antipsychotics are dosed to achieve equivalent D2 blockade (e.g., haloperidol 5 mg ≈ chlorpromazine 100 mg), they produce equivalent antipsychotic efficacy. The difference is in side-effect profile (sedation, anticholinergic effects), not antipsychotic potency. [cite:KD Tripathi 8e Ch 12]